Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Anil R. Diwan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Beta
- 1.66
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -22.03
Financials
Net Income
$-2.22MEBITDA
$-2.18MFree Cash Flow
$3.20TEPS (diluted)
$-0.11Shares Outstanding (diluted)
20.19M+594.0%Operating Expenses
$4.16TCash & Debt
$2.79TQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-8.22M | $-0.41 |
| 2025 | $0.00 | $-9.47M | $-0.63 |
| 2024 | $0.00 | $-8.29M | $-0.70 |
| 2023 | $0.00 | $-8.59M | $-0.74 |
| 2022 | $0.00 | $-8.11M | $-0.70 |
| 2021 | $0.00 | $-8.82M | $-0.81 |
| 2020 | $0.00 | $-13.45M | $-2.39 |
| 2019 | $0.00 | $-8.24M | $-2.30 |
| 2018 | $0.00 | $-8.56M | $-2.64 |
| 2017 | $0.00 | $-10.30M | $-3.43 |
| 2016 | $0.00 | $-10.72M | $-3.72 |
| 2015 | $0.00 | $-2.20M | $-0.78 |
| 2014 | $0.00 | $-14.11M | $-5.51 |
| 2013 | $0.00 | $-8.88M | $-3.87 |
Valuation
NNVChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60+0.00%Social Signal Score
Mentions (8)
- Newsaccessnewswire.com·1d ago·Negative
…nt for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives SHELTON, CT / ACCESS Newswire / October 5, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, herewith provides additional details on its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus (BDBV) and other Ebola viruses in the Democratic Republic of Congo ("DRC"). The trial i…
View source ↗ - Newsaccessnewswire.com·7d ago·Negative
…Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials SHELTON, CT / ACCESS Newswire / September 29, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2026 with the Securities and Exchange Commission (SEC) on Monday, September 28, 2026. The report can be accessed at the SEC website ( https://www.sec.gov/ix?doc=/Archives/edgar/data/0001379006/000110465926111390/nnvc-2…
View source ↗ - Newsaccessnewswire.com·8d ago·Negative
…osing of Patients Last Week (on or about September 23rd), Says NanoViricides SHELTON, CT / ACCESS Newswire / September 28, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of Congo ("DRC") has started enrolling and dosing patients at…
View source ↗ - Newsaccessnewswire.com·13d ago·Negative
…as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides SHELTON, CT / ACCESS Newswire / September 23, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that the Phase II Clinical Trial of the Company's Novel Broad-Spectrum Antiviral Drug NV-387 as a Treatment for Monkeypox Virus Infection has begun with enrollment of first patients in the Democratic Republic of Congo (DRC). This clinical trial was registered in the Pan African Clinical Trials R…
View source ↗ - Newsaccessnewswire.com·28d ago·Negative
…is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo SHELTON, CT / ACCESS Newswire / September 8, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of Congo ("DRC") was successfully registered in the Pan Afric…
View source ↗ - Newsaccessnewswire.com·36d ago·Negative
…rum Drug Candidate NV-387 as A Treatment for Measles SHELTON, CT / ACCESS Newswire / August 31, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American: NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, provides an update on its Measles Drug Treatment Program. While CDC is reviewing the two recent measles-related fatalities in Pennsylvania, the…
View source ↗ - Newsaccessnewswire.com·49d ago·Negative
…ngo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon SHELTON, CT / ACCESS Newswire / August 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses is expected to begin soon in the Democratic Republic of Congo ("DRC"). Professor Patrick…
View source ↗ - Newsaccessnewswire.com·57d ago·Negative
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak SHELTON, CT / ACCESS Newswire / August 10, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has received regulatory approval to begin a Phase II Clinical Trial of NV-387 Oral Gummies as
View source ↗
Earnings
Typical surprise +24.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Sep 28$-0.10 vs $-0.10beat
- Wed, Sep 2$-0.11 vs $-0.10miss
- Thu, May 21$-0.10 vs $-0.13beat
- Tue, Feb 17$-0.11 vs $-0.14beat
- Fri, Nov 14$-0.10 vs $-0.18beat
- Mon, Sep 29$-0.13 vs $-0.20beat
Estimates and results for NNVC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NNVC officers and directors.
- Bought
- $2.9m
- Sold
- $751k
58 trades
1 trade
- Boniuk Miltonbought
- Boniuk Miltonbought
- Boniuk Miltonbought
- Boniuk Miltonbought
- Boniuk Miltonbought
- Boniuk Miltonbought
- Boniuk Miltonbought
- Boniuk Miltonbought
41 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Kelly Loefflersenate · GA · disclosed May 1, 2020 (24d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.